Non-squamous non-small cell lung cancer
Showing 1 - 25 of >10,000
Non Squamous Non Small Cell Lung Cancer, EGFR Positive NSCLC Trial (Toripalimab plus Chemotherapy)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- EGFR Positive Non-small Cell Lung Cancer
- Toripalimab plus Chemotherapy
- (no location specified)
Jul 28, 2023
NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Cadonilimab
- +2 more
-
Wuhan, Hubei, ChinaQian Chu
Aug 18, 2023
Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung
Not yet recruiting
- Advanced Non-squamous Non-small-cell Lung Cancer
- +2 more
- pembrolizumab
- +2 more
-
Beijing, Beijing, ChinaPeking University First Hospital Ethics Committee
Sep 10, 2023
NSCLC Trial in Pittsburgh (Tiragolumab, Atezolizumab, Pemetrexed)
Not yet recruiting
- Non-small Cell Lung Cancer
- Tiragolumab
- +3 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Feb 16, 2023
Non-squamous NSCLC, Epithelial Ovarian Cancer Trial (AMG 794)
Not yet recruiting
- Non-squamous Non-small Cell Lung Cancer
- Epithelial Ovarian Cancer
- AMG 794
-
Orange, CaliforniaUniversity of California at Irvine
Jan 25, 2023
Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or
Not yet recruiting
- Non-squamous Non-small-cell Lung Cancer
- Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
- +2 more
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
May 5, 2023
Non Squamous Non Small Cell Lung Cancer Trial in Korea, Republic of (Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin)
Not yet recruiting
- Non Squamous Non Small Cell Lung Cancer
- Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
-
Anam, Korea, Republic of
- +7 more
May 1, 2023
Advanced Non-squamous Non-Small-Cell Lung Cancer Trial in Jinan (Sintilimab)
Recruiting
- Advanced Non-squamous Non-Small-Cell Lung Cancer
-
Jinan, Shandong, ChinaThe First Affiliated Hospital of Shandong First Medical Universi
Dec 4, 2022
Non-squamous Non-small-cell Lung Cancer, Brain Metastases Trial in Guangzhou (Camrelizumab, Pemetrexed, Carboplatin)
Active, not recruiting
- Non-squamous Non-small-cell Lung Cancer
- Brain Metastases
- Camrelizumab
- +2 more
-
Guangzhou, Guangzhou, ChinaLi-Kun Chen
Nov 13, 2022
NSCLC Trial in Wuhan (Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel)
Recruiting
- Non-small Cell Lung Cancer
- Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel
-
Wuhan, Hubei, ChinaUnion hospital
Feb 20, 2023
Non-squamous NSCLC Trial in Guangzhou (FSRT combined with Bevacizumab)
Active, not recruiting
- Non-squamous Non-small Cell Lung Cancer
- FSRT combined with Bevacizumab
-
Guangzhou, ChinaSun Yat-sen University
Nov 25, 2022
NSCLC Trial in Pittsburgh (M1774, Cemiplimab)
Not yet recruiting
- Non-Small Cell Lung Cancer
-
Pittsburgh, PennsylvaniaUPMC Cancer Center
May 22, 2023
NSCLC Metastatic Trial (bevacizumab plus nab-paclitaxel and platinum)
Not yet recruiting
- Non-small Cell Lung Cancer Metastatic
- bevacizumab plus nab-paclitaxel and platinum
- (no location specified)
Jun 2, 2022
Lung Cancer, Non Small Cell Lung Cancer, Adenocarcinoma of Lung Trial run by the National Cancer Institute (NCI) (LMB-100,
Active, not recruiting
- Lung Cancer
- +2 more
- LMB-100
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Oct 4, 2022
NSCLC Trial in Guangzhou (Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin)
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Guangzhou, Guang Dong, ChinaSun Yat-sen University Cancer Center
Nov 3, 2022
NSCLC, Brain Tumors Trial (bevacizumab, First-Line Chemotherapy Agents, Second-Line Chemotherapy Agents)
Completed
- Non-Small Cell Lung Cancer
- Brain Neoplasms
- bevacizumab
- +2 more
- (no location specified)
Dec 9, 2022
Non-squamous Non-small-cell Lung Cancer, Stage IV NSCLC, ROS1 Gene Rearrangement Trial in Toronto (Crizotinib)
Recruiting
- Non-squamous Non-small-cell Lung Cancer
- +4 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jan 8, 2023
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,
Not yet recruiting
- Non Small Cell Lung Cancer
- +2 more
- Pembrolizumab, pemetrexed, platinum
- Osimertinib
-
Peking, ChinaPeking Union Medical College Hospital
Nov 16, 2023
Advanced NSCLC Trial in Jilin (pemetrexed, Cetuximab, cis-platinum)
Not yet recruiting
- Advanced Non-Small Cell Lung Cancer
- pemetrexed
- +5 more
-
Jilin, Changchun, ChinaJilin Province Cancer Hospital
Aug 15, 2022
Non-squamous NSCLC Trial in Nanjing (paclitaxel polymeric micelles for injection)
Not yet recruiting
- Non-squamous NSCLC
- paclitaxel polymeric micelles for injection
-
Nanjing, Jiangsu, China
- +1 more
Mar 13, 2023
Non-squamous Non-small-cell Lung Cancer Trial in Beijing (SIBP04, Avastin, Paclitaxel)
Recruiting
- Non-squamous Non-small-cell Lung Cancer
- SIBP04
- +3 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 7, 2022
NSCLC Trial (Bemcentinib, Pembrolizumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Bemcentinib
- +3 more
- (no location specified)
Jul 19, 2022
First Line Crizotinib for ALK Rearranged Non-squamous Non-small
Recruiting
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaHunan Cancer Hospital
Mar 1, 2022